Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

4(50.0%)

Phase 2

3(37.5%)

Phase 1

1(12.5%)

8Total

Phase 4(4)

Phase 2(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT00400738Phase 2Completed

The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients

Role: collaborator

NCT01109498Phase 2Unknown

Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]

Role: collaborator

NCT00389402Phase 4Completed

BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes

Role: lead

NCT00389194Phase 4Completed

PREventing Progression of Adipose Tissue Redistribution

Role: lead

NCT00748436Phase 2Completed

Efficacy Study of Betahistine on Body Weight in Obese Female Subjects

Role: collaborator

NCT00127972Phase 4Completed

2NN & CHARM Long-Term Follow-up Study

Role: lead

NCT00128063Phase 1Completed

Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection

Role: lead

NCT00127959Phase 4Completed

Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection

Role: lead

All 8 trials loaded